Alector, Inc.: peers
Alector, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Alector, Inc.base ALEC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Vogenx, Inc. VOGX · 🇺🇸 US Percentile in Healthcare Percentile in USA | SAB Biotherapeutics, Inc. SABS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Eikon Therapeutics, Inc. EIKN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Agenus Inc. AGEN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Fulcrum Therapeutics, Inc. FULC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Benitec Biopharma Inc. BNTC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Yarrow Bioscience, Inc. YARW · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $293 MOct 21, 2026 · Market data4th of 8 | $296 MOct 30, 2026 · Market data3rd of 8 | $291 MOct 30, 2026 · Market data5th of 8 | $290 MOct 30, 2026 · Market data6th of 8 | $290 MOct 22, 2026 · Market data7th of 8 | $283 MOct 28, 2026 · Market data8th of 8 | $307 MOct 29, 2026 · Market data1st of 8 | $307 MOct 28, 2026 · Market data2nd of 8 | $292 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | —— | $114 MFY2025 · SEC1st of 2 | —— | —— | $1 MFY2025 · SEC2nd of 2 | $57 M2 ranked |
| Net income (Higher is better) | $-143 MFY2025 · SEC6th of 6 | —— | $13 MFY2025 · SEC1st of 6 | —— | $-3 MFY2025 · SEC2nd of 6 | $-75 MFY2025 · SEC5th of 6 | $-46 MFY2026 · SEC4th of 6 | $-26 MFY2025 · SEC3rd of 6 | $-36 M6 ranked |
| Employees (Better neither way: ranked highest first) | 185As on 2021 · Profile3rd of 6 | —— | 86December 31, 2025 · Profile5th of 6 | 384December 31, 2025 · Profile2nd of 6 | 441As on 2021 · Profile1st of 6 | 104As on 2021 · Profile4th of 6 | —— | 10December 31, 2025 · Profile6th of 6 | 1456 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | —— | —— | —— | -26.4%30 days to Oct 22, 2026 · Market dataonly one with it | —— | —— | —— | -26.4%— |
| Revenue growth (Higher is better) | ———— | ———— | ———— | ———— | +10.4%FY2025 · SEConly one with it50th62nd | ———— | ———— | ———— | +10.4%— |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | +5.2%FY2025 · SEConly one with it42nd54th | ———— | ———— | ———— | +5.2%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | ———— | 99.1%FY2025 · SEConly one with it99th100th | ———— | ———— | ———— | 99.1%— |
| Operating margin (Higher is better) | ———— | ———— | ———— | ———— | -17.7%FY2025 · SEConly one with it43rd22nd | ———— | ———— | ———— | -17.7%— |
| Net margin (Higher is better) | ———— | ———— | ———— | ———— | -2.7%FY2025 · SEConly one with it57th37th | ———— | ———— | ———— | -2.7%— |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | -67.6%FY2025 · SEConly one with it25th10th | ———— | ———— | ———— | -67.6%— |
| Return on equity (Higher is better) | -181.6%FY2025 · SEC4th of 413th5th | ———— | 14.9%FY2025 · SEC1st of 487th78th | ———— | ———— | -25.3%FY2025 · SEC2nd of 457th26th | -33.2%FY2026 · SEC3rd of 452nd23rd | ———— | -29.3%4 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | 21.9×price Oct 30, 2026 · Market data1st of 235th58th | ———— | 9.4×price Oct 22, 2026 · Market data2nd of 213th14th | ———— | ———— | ———— | 15.7×2 ranked |
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 2.2×price Oct 22, 2026 · Market data2nd of 235th50th | ———— | ———— | 537.8×price Oct 28, 2026 · Market data1st of 299th100th | 270.0×2 ranked |
| Price to book (Better neither way: ranked highest first) | 9.6×price Oct 21, 2026 · Market data1st of 483rd89th | ———— | 1.9×price Oct 30, 2026 · Market data2nd of 438th46th | ———— | ———— | 0.8×price Oct 28, 2026 · Market data4th of 415th15th | 1.7×price Oct 29, 2026 · Market data3rd of 435th42nd | ———— | 1.8×4 ranked |
| Free cash flow yield (Higher is better) | -62.8%price Oct 21, 2026 · Market data6th of 615th6th | ———— | -15.7%price Oct 30, 2026 · Market data3rd of 637th17th | ———— | -26.7%price Oct 22, 2026 · Market data5th of 628th12th | -21.4%price Oct 28, 2026 · Market data4th of 632nd14th | -5.4%price Oct 29, 2026 · Market data1st of 654th26th | -10.8%price Oct 28, 2026 · Market data2nd of 642nd20th | -18.5%6 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 0.3×FY2025 · SEConly one with it42nd32nd | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 0.3×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | —— | 4 of 9FY2025 · SEConly one with it | —— | —— | —— | 4.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 4 of 12FY2025 · Scorecard4th of 8 | 0 of 2FY2025 · Scorecard8th of 8 | 3 of 11FY2025 · Scorecard5th of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 8 of 18FY2025 · Scorecard2nd of 8 | 2 of 12FY2025 · Scorecard6th of 8 | 2 of 12FY2026 · Scorecard6th of 8 | 6 of 17FY2025 · Scorecard3rd of 8 | 30% passed8 ranked |
| Valuation checks (Higher is better) | 0 of 2FY2025 · Scorecard5th of 8 | 0 of 1FY2025 · Scorecard5th of 8 | 1 of 4FY2025 · Scorecard2nd of 8 | 0 of 1FY2025 · Scorecard5th of 8 | 3 of 5FY2025 · Scorecard1st of 8 | 1 of 4FY2025 · Scorecard2nd of 8 | 1 of 4FY2026 · Scorecard2nd of 8 | 0 of 5FY2025 · Scorecard5th of 8 | 13% passed8 ranked |
| Growth checks (Higher is better) | 1 of 2FY2025 · Scorecard2nd of 6 | —— | 0 of 2FY2025 · Scorecard4th of 6 | —— | 3 of 5FY2025 · Scorecard1st of 6 | 0 of 2FY2025 · Scorecard4th of 6 | 0 of 2FY2026 · Scorecard4th of 6 | 1 of 3FY2025 · Scorecard3rd of 6 | 17% passed6 ranked |
| Profitability checks (Higher is better) | 0 of 3FY2025 · Scorecard3rd of 6 | —— | 1 of 3FY2025 · Scorecard2nd of 6 | —— | 2 of 4FY2025 · Scorecard1st of 6 | 0 of 3FY2025 · Scorecard3rd of 6 | 0 of 3FY2026 · Scorecard3rd of 6 | 0 of 3FY2025 · Scorecard3rd of 6 | 0% passed6 ranked |
| Financial health checks (Higher is better) | 3 of 4FY2025 · Scorecard3rd of 8 | 0 of 1FY2025 · Scorecard7th of 8 | 1 of 2FY2025 · Scorecard4th of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard7th of 8 | 1 of 2FY2025 · Scorecard4th of 8 | 1 of 2FY2026 · Scorecard4th of 8 | 4 of 5FY2025 · Scorecard2nd of 8 | 50% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard2nd of 5 | —— | —— | —— | 0 of 1FY2025 · Scorecard2nd of 5 | 0 of 1FY2025 · Scorecard2nd of 5 | 0 of 1FY2026 · Scorecard2nd of 5 | 1 of 1FY2025 · Scorecard1st of 5 | 0% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 63.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 53.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 87.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 58.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 58.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 102.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 96.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 61.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 62.8%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 1372026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 1022026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 982026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 1252026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 1512026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 912026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 492026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 1008 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +6.2 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | —— | -61.4 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | +5.1 pp2026-Q2 against 2026-Q1 · 13F4th of 6 | +7.7 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | +4.8 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | +5.1 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | —— | +5.1 pp6 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Alector, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vogenx, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; SAB Biotherapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Eikon Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Agenus Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Fulcrum Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Benitec Biopharma Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Yarrow Bioscience, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Alector, Inc. | — | — | — |
| Vogenx, Inc. | — | — | — |
| SAB Biotherapeutics, Inc. | — | — | — |
| Eikon Therapeutics, Inc. | — | — | — |
| Agenus Inc. | -17.7%FY2025 | 43rd percentile in Healthcaremedian -8.0%, 684 companies | 22nd percentile in USAmedian 3.5%, 2,595 companies |
| Fulcrum Therapeutics, Inc. | — | — | — |
| Benitec Biopharma Inc. | — | — | — |
| Yarrow Bioscience, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Alector, Inc. | Vogenx, Inc. | SAB Biotherapeutics, Inc. | Eikon Therapeutics, Inc. | Agenus Inc. | Fulcrum Therapeutics, Inc. | Benitec Biopharma Inc. | Yarrow Bioscience, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | $114 MSEC1st | — | — | $1 MSEC2nd |
| 2024 | $101 MSEC2nd | — | $1 MSEC4th | — | $103 MSEC1st | $80 MSEC3rd | — | $1 MSEC5th |
| 2023 | $97 MSEC2nd | — | $2 MSEC4th | — | $156 MSEC1st | $3 MSEC3rd | $0 MSEC6th | $0 MSEC5th |
| 2022 | $134 MSEC1st | — | $24 MSEC3rd | — | $98 MSEC2nd | $6 MSEC4th | $0 MSEC6th | $0 MSEC5th |
| 2021 | $207 MSEC1st | — | $61 MSEC2nd | — | — | $19 MSEC3rd | $0 MSEC5th | $1 MSEC4th |
| 2020 | $21 MSEC3rd | — | $55 MSEC2nd | — | $88 MSEC1st | $9 MSEC5th | $0 MSEC6th | $21 MSEC4th |
| 2019 | $21 MSEC2nd | — | — | — | $150 MSEC1st | — | $12 MSEC3rd | $0 MSEC4th |
| 2018 | $28 MSEC2nd | — | — | — | $37 MSEC1st | — | — | $11 MSEC3rd |
| 2017 | — | — | — | — | $43 MSEC1st | — | — | $5 MSEC2nd |
| 2016 | — | — | — | — | $23 MSEC1st | — | — | $1 MSEC2nd |
| 2015 | — | — | — | — | $25 MSEC | — | — | — |
| 2014 | — | — | — | — | $7 MSEC | — | — | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Alector, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Vogenx, Inc.VOGX · 🇺🇸 USASame industry: Biotechnology · Similar size: $296 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $296 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- SAB Biotherapeutics, Inc.SABS · 🇺🇸 USASame industry: Biotechnology · Similar size: $291 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $291 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Eikon Therapeutics, Inc.EIKN · 🇺🇸 USASame industry: Biotechnology · Similar size: $290 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $290 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Agenus Inc.AGEN · 🇺🇸 USASame industry: Biotechnology · Similar size: $290 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $290 M (Oct 22, 2026) · revenue $114 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Fulcrum Therapeutics, Inc.FULC · 🇺🇸 USASame industry: Biotechnology · Similar size: $283 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $283 M (Oct 28, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Benitec Biopharma Inc.BNTC · 🇺🇸 USASame industry: Biotechnology · Similar size: $307 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $307 M (Oct 29, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Yarrow Bioscience, Inc.YARW · 🇺🇸 USASame industry: Biotechnology · Similar size: $307 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $307 M (Oct 28, 2026) · revenue $1 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Evommune, Inc.EVMN · 🇺🇸 USASame industry: Biotechnology · Similar size: $282 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $282 M (Oct 30, 2026) · revenue $13 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Greenwich LifeSciences, Inc.GLSI · 🇺🇸 USASame industry: Biotechnology · Similar size: $279 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $279 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Lyell Immunopharma, Inc.LYEL · 🇺🇸 USASame industry: Biotechnology · Similar size: $278 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $278 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Prelude Therapeutics IncorporatedPRLD · 🇺🇸 USASame industry: Biotechnology · Similar size: $311 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $311 M (Oct 28, 2026) · revenue $12 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Rocket Pharmaceuticals, Inc.RCKT · 🇺🇸 USASame industry: Biotechnology · Similar size: $274 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $274 M (Oct 28, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.